Advanced search
Publication Cover
Expert Review of Anticancer Therapy Volume 21, 2021 - Issue 11
Submit an article Journal homepage
241
Views
1
CrossRef citations to date
0
Altmetric
Meeting report

Inside prostate cancer news from the 2021 ASCO Genitourinary Cancers Symposium

Roberto Iacovellia Department of Medical Oncology, Fondazione Policlinico Universitario A. Gemelli Irccs, Rome, ItalyCorrespondence[email protected]
View further author information
,
Serena Astorea Department of Medical Oncology, Fondazione Policlinico Universitario A. Gemelli Irccs, Rome, ItalyView further author information
,
Chiara Ciccaresea Department of Medical Oncology, Fondazione Policlinico Universitario A. Gemelli Irccs, Rome, Italy;b Department of Medical Oncology, Università Cattolica Del Sacro Cuore, Rome, ItalyView further author information
,
Maria Antonella Cannellaa Department of Medical Oncology, Fondazione Policlinico Universitario A. Gemelli Irccs, Rome, ItalyView further author information
,
Pierluigi Bovec Department of Urology, San Carlo di Nancy Hospital, Rome, ItalyView further author information
,
Valerio Iacovellic Department of Urology, San Carlo di Nancy Hospital, Rome, ItalyView further author information
&
Giampaolo Tortoraa Department of Medical Oncology, Fondazione Policlinico Universitario A. Gemelli Irccs, Rome, Italy;b Department of Medical Oncology, Università Cattolica Del Sacro Cuore, Rome, ItalyView further author information
 show all
Pages 1207-1210 | Received 03 May 2021, Accepted 24 Aug 2021, Published online: 09 Sep 2021

References

  • Small EJ, Saad F, Chowdhury S, et al. Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer. Ann Oncol. 2019;30(11):1813–1820.
  • Fizazi K, Shore N, Tammela TL, et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2019;380(13):1235–1246.
  • Sternberg CN, Fizazi K, Saad F, et al. Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2020;382(23):2197–2206.
  • Feng FY, Aguilar-Bonavides C, Lucas J, et al. Molecular determinants associated with long-term response to apalutamide (APA) in nonmetastatic castration-resistant prostate cancer (nmCRPC). J Clin Oncol. 2021;39(6_suppl):8.
  • Feng FY, Thomas S, Gormley M, et al. Identifying molecular determinants of response to apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in the SPARTAN trial. J Clin oncol. 2019;37(7_suppl):42.
  • Robinson D, Van Allen EM, Wu YM, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161(5):1215–1228.
  • Pritchard CC, Mateo J, Walsh MF, et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med. 2016 Aug 4;375(5):443–453.
  • De Bono J, Mateo J, Fizazi K, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382(22):2091–2102.
  • Chi KN, Barnicle A, Sibilla C, et al. Concordance of BRCA1, BRCA2 (BRCA), and ATM mutations identified in matched tumor tissue and circulating tumor DNA (ctDNA) in men with metastatic castration-resistant prostate cancer (mCRPC) screened in the PROfound study. J Clin Oncol. 2021;39(6_suppl):26.
  • Matsubara N, De Bono JS, Olmos D, et al. Olaparib efficacy in patients with metastatic castration-resistant prostate cancer (mCRPC) carrying circulating tumor (ct) DNA alterations in BRCA1, BRCA2 or ATM: results from the PROfound study. J Clin Oncol. 2021;39(6_suppl):27.
  • Appleman LJ, Kolinsky MP, Berry WR, et al. KEYNOTE-365 cohort B: pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)–pretreated patients with metastatic castration-resistant prostate cancer (mCRPC)—New data after an additional 1 year of follow-up. J Clin Oncol. 2021;39(6_suppl):10.
  • Fizazi K, Mella PG, Castellano D, et al. CheckMate 9KD Arm B final analysis: efficacy and safety of nivolumab plus docetaxel for chemotherapy-naïve metastatic castration-resistant prostate cancer. J Clin Oncol. 2021;39(6_suppl):12.
  • Gannon PO, Poisson AO, Delvoye N, et al. Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. J Immunol Methods. 2009;348(1–2):9–17.
  • Vidotto T, Saggioro FP, Jamaspishvili T, et al. PTEN-deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cells. Prostate. 2019;79(9):969–979.
  • Carver BS, Chapinski C, Wongvipat, et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell. 2011;19(5):575–586.
  • De Bono JS, Bracarda S, Sternberg CN, et al. IPATential150: phase III study of ipatasertib plus abiraterone vs placebo plus abiraterone in metastatic castration-resistant prostate cancer. In ESMO Virtual Congress 2020. Abstract LBA4. Presented 2020 Sept 20.
  • De Bono JS, Sweeney C, Bracarda S, et al. PI3K/AKT pathway biomarkers analysis from the phase III IPATential150 trial of ipatasertib plus abiraterone in metastatic castration-resistant prostate cancer. J Clin Oncol. 2021;39(6_suppl):13.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.